📧 Communication
Meeting / WarningCommunication Details
From
F.D.A.
Linked to F.D.A.
To
Celgene
Celgene
Date
December 01, 1998
Subject
Marketing of Thalomid
Message Content
The F.D.A. called a meeting to warn Celgene of its 'strong concern' that the company was marketing Thalomid for unapproved uses.
📄 Source Document
HOUSE_OVERSIGHT_028418.jpg
ESTATE Collection
Document Summary
This document is a digital article, labeled for a House Oversight investigation, concerning the pharmaceutical company Celgene and its executive, Mr. Hugin. It details the company's aggressive marketing of the drug Thalomid for unapproved uses shortly after its launch, leading to multiple reprimands from the F.D.A. in the late 1990s and a whistle-blower lawsuit settled in 2017. The document is not related to Jeffrey Epstein.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein communication